BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 26692014)

  • 1. Molecular basis of antibody binding to mucin glycopeptides in lung cancer.
    Qu J; Yu H; Li F; Zhang C; Trad A; Brooks C; Zhang B; Gong T; Guo Z; Li Y; Ragupathi G; Lou Y; Hwu P; Huang W; Zhou D
    Int J Oncol; 2016 Feb; 48(2):587-94. PubMed ID: 26692014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MUC1 glycopeptide epitopes predicted by computational glycomics.
    Song W; Delyria ES; Chen J; Huang W; Lee JS; Mittendorf EA; Ibrahim N; Radvanyi LG; Li Y; Lu H; Xu H; Shi Y; Wang LX; Ross JA; Rodrigues SP; Almeida IC; Yang X; Qu J; Schocker NS; Michael K; Zhou D
    Int J Oncol; 2012 Dec; 41(6):1977-84. PubMed ID: 23023583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice.
    Ryan SO; Vlad AM; Islam K; Gariépy J; Finn OJ
    Biol Chem; 2009 Jul; 390(7):611-8. PubMed ID: 19426130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epitopes of MUC1 Tandem Repeats in Cancer as Revealed by Antibody Crystallography: Toward Glycopeptide Signature-Guided Therapy.
    Zhou D; Xu L; Huang W; Tonn T
    Molecules; 2018 May; 23(6):. PubMed ID: 29857542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure/activity studies of the anti-MUC1 monoclonal antibody C595 and synthetic MUC1 mucin-core-related peptides and glycopeptides.
    Spencer DI; Missailidis S; Denton G; Murray A; Brady K; Matteis CI; Searle MS; Tendler SJ; Price MR
    Biospectroscopy; 1999; 5(2):79-91. PubMed ID: 10217327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An essential epitope of anti-MUC1 monoclonal antibody KL-6 revealed by focused glycopeptide library.
    Ohyabu N; Hinou H; Matsushita T; Izumi R; Shimizu H; Kawamoto K; Numata Y; Togame H; Takemoto H; Kondo H; Nishimura S
    J Am Chem Soc; 2009 Dec; 131(47):17102-9. PubMed ID: 19899793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.
    Sørensen AL; Reis CA; Tarp MA; Mandel U; Ramachandran K; Sankaranarayanan V; Schwientek T; Graham R; Taylor-Papadimitriou J; Hollingsworth MA; Burchell J; Clausen H
    Glycobiology; 2006 Feb; 16(2):96-107. PubMed ID: 16207894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma.
    Stepensky D; Tzehoval E; Vadai E; Eisenbach L
    Clin Exp Immunol; 2006 Jan; 143(1):139-49. PubMed ID: 16367945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat.
    Tarp MA; Sørensen AL; Mandel U; Paulsen H; Burchell J; Taylor-Papadimitriou J; Clausen H
    Glycobiology; 2007 Feb; 17(2):197-209. PubMed ID: 17050588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibody BW835 defines a site-specific Thomsen-Friedenreich disaccharide linked to threonine within the VTSA motif of MUC1 tandem repeats.
    Hanisch FG; Stadie T; Bosslet K
    Cancer Res; 1995 Sep; 55(18):4036-40. PubMed ID: 7545084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microarray Analysis of Antibodies Induced with Synthetic Antitumor Vaccines: Specificity against Diverse Mucin Core Structures.
    Pett C; Cai H; Liu J; Palitzsch B; Schorlemer M; Hartmann S; Stergiou N; Lu M; Kunz H; Schmitt E; Westerlind U
    Chemistry; 2017 Mar; 23(16):3875-3884. PubMed ID: 27957769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced binding of antibodies to the DTR motif of MUC1 tandem repeat peptide is mediated by site-specific glycosylation.
    Karsten U; Diotel C; Klich G; Paulsen H; Goletz S; Müller S; Hanisch FG
    Cancer Res; 1998 Jun; 58(12):2541-9. PubMed ID: 9635576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specificity clusters of MUC1-reactive mouse monoclonal antibodies.
    Hanisch FG
    Tumour Biol; 1998; 19 Suppl 1():111-7. PubMed ID: 9422095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibodies toward different Tn-amino acid backbones display distinct recognition patterns on human cancer cells. Implications for effective immuno-targeting of cancer.
    Mazal D; Lo-Man R; Bay S; Pritsch O; Dériaud E; Ganneau C; Medeiros A; Ubillos L; Obal G; Berois N; Bollati-Fogolin M; Leclerc C; Osinaga E
    Cancer Immunol Immunother; 2013 Jun; 62(6):1107-22. PubMed ID: 23604173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structurally defined synthetic cancer vaccines: analysis of structure, glycosylation and recognition of cancer associated mucin, MUC-1 derived peptides.
    Liu X; Sejbal J; Kotovych G; Koganty RR; Reddish MA; Jackson L; Gandhi SS; Mendonca AJ; Longenecker BM
    Glycoconj J; 1995 Oct; 12(5):607-17. PubMed ID: 8595249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of glycosylation on the ensemble of conformations in the MUC1 immunodominant epitope.
    Singh J; Her C; Supekar N; Boons GJ; Krishnan VV; Brooks CL
    J Pept Sci; 2020 Jan; 26(1):e3229. PubMed ID: 31729101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specificities of anti-sialyl-Tn and anti-Tn monoclonal antibodies generated using novel clustered synthetic glycopeptide epitopes.
    Reddish MA; Jackson L; Koganty RR; Qiu D; Hong W; Longenecker BM
    Glycoconj J; 1997 Aug; 14(5):549-60. PubMed ID: 9298687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of a new MUC1 monoclonal antibody (VU-2-G7) directed to the glycosylated PDTR sequence of MUC1.
    Ryuko K; Schol DJ; Snijdewint FG; von Mensdorff-Pouilly S; Poort-Keesom RJ; Karuntu-Wanamarta YA; Verstraeten RA; Miyazaki K; Kenemans P; Hilgers J
    Tumour Biol; 2000; 21(4):197-210. PubMed ID: 10867613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Tumor-Selective Monoclonal Antibody from Immunization with a Tumor-Associated Mucin Glycopeptide.
    Trabbic KR; Whalen K; Abarca-Heideman K; Xia L; Temme JS; Edmondson EF; Gildersleeve JC; Barchi JJ
    Sci Rep; 2019 Apr; 9(1):5662. PubMed ID: 30952968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor immunity provided by a synthetic multiple antigenic glycopeptide displaying a tri-Tn glycotope.
    Lo-Man R; Vichier-Guerre S; Bay S; Dériaud E; Cantacuzène D; Leclerc C
    J Immunol; 2001 Feb; 166(4):2849-54. PubMed ID: 11160353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.